---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055054"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T08:35:22.153659+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics opens enrollment in CEDAR-HCM trial of aficamten in pediatric obstructive HCM

## Summary
- Initial cohort ~40 adolescents (12-17) with LVEF ≥60%, Valsalva LVOT-G ≥50 mmHg, NYHA ≥II.
- Dosing starts at 5 mg once daily; up-titration at Wk2/4/6 to 10/15/20 mg based on Valsalva LVOT-G ≥30 mmHg and LVEF ≥55%.
- Primary endpoint: change in Valsalva LVOT-G at Week 12; secondary endpoints include resting LVOT-G, NYHA class, PK, NT-proBNP, hs-cTnI.
- Second cohort of ~8-10 patients aged 6-11 will open after data from ≥20 adolescents complete Week 12.

## SEC filing metadata
- accession: 0000950170-24-055054
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000095017024055054/0000950170-24-055054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000095017024055054/cytk-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055054
- JSON: https://secwatch.observer/filing/0000950170-24-055054.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.